SKIN - The Beauty Health Company Stock Price, Fair Value and News

2.74USD-0.03 (-1.08%)Delayed

Market Summary

USD2.74-0.03

Delayed

-1.08%

SKIN Alerts

Big jump in Earnings (Y/Y)

Losses in recent quarter

SKIN Stock Price

View Fullscreen

SKIN RSI Chart

SKIN Valuation

Market Cap

338.8M

Price/Earnings (Trailing)

-4.21

Price/Sales (Trailing)

0.86

EV/EBITDA

-10.42

Price/Free Cashflow

21.1

SKIN Price/Sales (Trailing)

SKIN Profitability

Operating Margin

38.00%

EBT Margin

-19.92%

Return on Equity

-127.24%

Return on Assets

-9.53%

Free Cashflow Yield

4.74%

SKIN Fundamentals

SKIN Revenue

Revenue (TTM)

393.1M

Rev. Growth (Yr)

-5.65%

Rev. Growth (Qtr)

-15.92%

SKIN Earnings

Earnings (TTM)

-80.5M

Earnings Growth (Yr)

96.65%

Earnings Growth (Qtr)

92.78%

Breaking Down SKIN Revenue

Last 30 days

-17.2%

Last 90 days

-12.5%

Trailing 12 Months

-73.1%

How does SKIN drawdown profile look like?

SKIN Financial Health

Current Ratio

6.57

Debt/Equity

10.51

Debt/Cashflow

0.03

SKIN Investor Care

Buy Backs (1Y)

6.80%

Diluted EPS (TTM)

-0.7

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	393.1M	0	0	0
2023	376.7M	390.7M	399.3M	398.0M
2022	288.0M	325.0M	345.6M	365.9M
2021	306.5M	358.9M	392.5M	260.1M
2020	0	150.8M	134.9M	119.1M
2019	0	0	0	166.6M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of The Beauty Health Company

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 09, 2024	monahan michael p.	acquired	-	-	292,207	chief financial officer
Apr 09, 2024	beck marla malcolm	acquired	-	-	837,662	president and ceo
Apr 09, 2024	watson daniel copell	acquired	-	-	243,506	chief revenue oficer
Nov 29, 2023	hauser bradley	acquired	-	-	176,711	chief operating officer
Nov 29, 2023	watson daniel copell	acquired	-	-	156,250	chief revenue oficer
Nov 29, 2023	monahan michael p.	acquired	-	-	176,711	chief financial officer
Nov 20, 2023	beck marla malcolm	acquired	-	-	213,675	interim ceo
Aug 17, 2023	miller brian christopher	bought	348,600	5.81	60,000	-
Aug 17, 2023	capellas michael d	bought	180,948	6.0316	30,000	-
Aug 17, 2023	stanleick andrew roy	bought	99,815	6.0549	16,485	chief executive officer

Which funds bought or sold SKIN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Creekmur Asset Management LLC	sold off	-100	-389	-	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-61.12	-893,985	1,115,230	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-91.00	-245,070	36,146	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-257,555	-	-%
May 15, 2024	PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO	unchanged	-	22,000	75,000	-%
May 15, 2024	CITADEL ADVISORS LLC	added	60.43	3,118,600	5,535,350	-%
May 15, 2024	QUADRANT CAPITAL GROUP LLC	reduced	-74.66	-9,385	5,320	-%
May 15, 2024	Point72 Asset Management, L.P.	added	66.15	9,726,360	16,815,600	0.04%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-1,100,520	-	-%
May 15, 2024	JANUS HENDERSON GROUP PLC	reduced	-0.12	14,968,900	50,111,900	0.03%

Are Funds Buying or Selling SKIN?

Are funds buying SKIN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SKIN

No. of Funds

Unveiling The Beauty Health Company's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	janus henderson group plc	10.6%	13,238,594	SC 13G/A
Mar 14, 2024	lcp edge holdco llc	27.03%	33,360,741	SC 13D/A
Feb 14, 2024	luxor capital group, lp	1%	18,872	SC 13G/A
Feb 13, 2024	vanguard group inc	5.53%	7,258,870	SC 13G/A
Feb 13, 2024	janus henderson group plc	9.6%	12,716,793	SC 13G/A
Feb 09, 2024	senvest management, llc	0%	0	SC 13G/A
Jan 10, 2024	fmr llc	-	0	SC 13G/A
Dec 11, 2023	fmr llc	-	0	SC 13G/A
Nov 09, 2023	janus henderson group plc	10.1%	13,531,260	SC 13G/A
Feb 14, 2022	luxor capital group, lp	1%	143,628	SC 13G/A

Recent SEC filings of The Beauty Health Company

View All Filings

Date Filed	Form Type	Document
May 17, 2024	SC 13G	Major Ownership Report
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 02, 2024	8-K/A	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 11, 2024	4	Insider Trading
Apr 11, 2024	4	Insider Trading
Apr 11, 2024	4	Insider Trading
Apr 10, 2024	PRE 14A	PRE 14A

Peers (Alternatives to The Beauty Health Company)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
PG	395.7B	84.1B	6.80%	9.91%	26.16	4.71	3.82%	5.63%
CL	77.2B	19.8B	8.50%	18.11%	29.57	3.91	7.71%	63.39%
EL	48.4B	15.3B	-2.44%	-32.61%	72.94	3.15	-3.25%	-39.29%
CHD	26.0B	5.9B	2.80%	12.53%	33.35	4.38	8.05%	89.02%
CLX	16.8B	7.2B	-4.70%	-18.34%	70.19	2.34	0.53%	224.32%
COTY	9.2B	6.1B	0.19%	-6.00%	42.16	1.51	13.69%	13.11%
ELF	8.8B	890.1M	-4.70%	74.87%	67.98	9.88	79.24%	176.22%
MID-CAP
IPAR	4.0B	1.3B	0.70%	-6.53%	28.55	3	15.88%	-0.05%
NWL	3.4B	8.0B	17.03%	-8.34%	-11.41	0.42	-10.08%	-121.80%
HIMS	3.1B	959.4M	17.49%	41.97%	-1.3K	3.24	55.65%	96.05%
HELE	2.6B	2.0B	13.24%	10.40%	15.38	1.29	-3.26%	17.67%
SMALL-CAP
EPC	2.0B	2.3B	14.38%	-6.83%	16.18	0.88	1.98%	28.45%
ACU	144.4M	190.6M	-7.81%	61.36%	7.83	0.76	-2.98%	477.15%
GROV	55.5M	241.3M	0.66%	232.61%	-1.65	0.23	-20.28%	37.16%
UG	42.3M	11.6M	17.05%	-1.29%	15.37	3.65	1.70%	13.94%

The Beauty Health Company News

Latest updates

The Beauty Health Company Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Revenue	-15.9%	81,403,000	96,821,000	97,413,000	117,479,000	86,278,000	98,133,000	88,792,000	103,536,000	75,415,000	77,889,000	68,147,000	66,508,000	47,542,000	210,308,968	34,560,000	14,116,000	-
Cost Of Revenue	-35.4%	33,042,000	51,135,000	109,966,000	49,603,000	32,174,000	31,642,000	27,429,000	33,496,000	24,530,000	24,417,000	22,072,000	19,257,000	15,802,000	14,843,000	13,603,000	9,840,000	-
Gross Profit	5.9%	48,361,000	45,686,000	-12,553,000	67,876,000	54,104,000	66,491,000	61,363,000	70,040,000	50,885,000	53,472,000	46,075,000	47,251,000	31,740,000	23,037,000	20,957,000	4,276,000	-
Operating Expenses	2.0%	65,352,000	64,046,000	69,548,000	81,022,000	71,414,000	68,939,000	65,716,000	75,067,000	64,898,000	63,973,000	51,531,000	73,604,000	29,358,000	27,748,000	18,172,000	12,195,000	-
S&GA Expenses	5.2%	33,684,000	32,025,000	30,731,000	43,041,000	38,699,000	39,021,000	39,767,000	44,881,000	36,407,000	37,438,000	30,451,000	26,214,000	17,095,000	15,898,500	10,541,000	6,186,000	-
R&D Expenses	-7.8%	2,807,000	3,046,000	1,839,000	2,881,000	2,336,000	1,446,000	2,167,000	2,601,000	2,230,000	1,875,000	1,880,000	2,988,000	1,452,000	859,500	577,000	597,000	-
EBITDA Margin	30.2%	-0.14	-0.20	-0.17	0.01	0.02	0.18	0.11	-0.56	-1.13	-1.40	-0.90	-0.39	-	-	-	-	-
Interest Expenses	-9.8%	3,029,000	3,358,000	3,445,000	3,429,000	3,417,000	3,395,000	3,380,000	3,217,000	3,400,000	1,528,000	-	7,126,000	3,123,000	3,104,000	3,171,000	3,111,000	-
Income Taxes	-216.1%	-700,000	603,000	3,479,000	-2,193,000	-3,662,000	-780,500	-800,000	76,000	2,615,000	1,427,500	-1,100,000	-1,900,000	-300,000	-3,048,500	-593,000	-3,052,000	-
Earnings Before Taxes	82.8%	-1,338,000	-7,787,000	-70,339,000	1,171,000	-25,947,000	5,778,000	-902,000	6,393,000	34,070,000	-19,537,000	-216,274,000	-141,248,000	-3,580,000	-10,542,000	-2,807,000	-13,449,000	-
EBT Margin	23.0%	-0.20	-0.26	-0.22	-0.05	-0.04	0.12	0.06	-0.60	-1.19	-1.46	-0.95	-0.44	-	-	-	-	-
Net Income	92.8%	-679,000	-9,403,000	-73,818,000	3,364,000	-20,259,000	6,533,000	-81,000	6,317,000	31,455,000	-20,967,000	-215,145,000	-139,378,000	-3,274,000	-7,494,000	-2,214,000	-10,397,000	-
Net Income Margin	18.6%	-0.20	-0.25	-0.21	-0.03	-0.02	0.12	0.05	-0.61	-1.19	-1.46	-0.93	-0.42	-	-	-	-	-
Free Cashflow	-230.9%	-17,198,000	-5,198,000	17,790,000	20,662,000	-15,329,000	-6,360,000	-35,704,000	-33,763,000	-41,620,000	-3,065,000	148,000	-37,088,000	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-9.1%	845	929	973	1,007	995	1,003	1,105	1,215	1,199	1,219	998	343	464	223	225	226
Current Assets	-11.9%	615	698	738	768	749	783	892	996	982	1,001	798	174	3.00	59.00	-	54.00
Cash Equivalents	-15.0%	445	523	559	550	532	568	684	821	859	902	719	101	14.00	9.00	12.00	7.00
Inventory	4.8%	96.00	91.00	75.00	107	122	110	102	74.00	47.00	35.00	28.00	24.00	22.00	23.00	-	19.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	12.00	10.00	8.00	9.00	-	11.00
Goodwill	-0.4%	125	126	125	125	125	125	123	4.00	124	124	123	103	99.00	99.00	99.00	99.00
Liabilities	-10.2%	781	870	883	846	847	836	847	863	857	917	1,140	326	68.00	253	-	228
Current Liabilities	-18.6%	94.00	115	126	83.00	72.00	72.00	76.00	87.00	69.00	76.00	49.00	39.00	1.00	31.00	0.00	38.00
Long Term Debt	-9.9%	665	738	737	736	735	734	733	732	731	730	729	-	218	-	-	181
LT Debt, Non Current	-100.0%	-	738	737	736	735	734	733	732	731	730	729	-	218	-	-	181
Shareholder's Equity	6.6%	63.00	59.00	90.00	162	152	167	251	345	336	298	-	16.00	-	5.00	0.00	-
Retained Earnings	-0.1%	-479	-478	-469	-395	5.00	-378	-378	-378	-386	-418	-401	-186	-68.02	-43.60	0.00	-14.43
Additional Paid-In Capital	1.0%	547	541	565	561	555	550	643	736	729	722	261	202	3.00	14.00	0.00	14.00
Shares Outstanding	0.5%	123	123	133	133	133	132	151	151	151	102	132	64.00	-	-	-	-
Float	-	-	-	-	729	-	-	-	1,340	-	-	-	1,410	-	558	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Cashflow From Operations	-226.0%	-16,854	-5,170	17,964	21,966	-13,010	-5,393	-31,401	-31,335	-38,471	3,279	298	-33,199	1,261	-752	-540*	-6,579	-5,054	-	-
Share Based Compensation	193.9%	6,636	2,258	8,185	8,524	3,577	7,619	7,449	6,378	7,049	3,794	5,082	3,508	34.00	37.00	76.00	224	26.00	-	-
Cashflow From Investing	16.9%	-1,802	-2,168	-4,436	-3,219	-21,684	-2,824	-7,741	-4,879	-3,425	-8,530	-20,082	-8,131	-988	-1,120	-1,272	818	-2,243	-	-
Cashflow From Financing	-86.9%	-58,618	-31,357	-2,350	-1,546	-2,195	-102,479	-100,000	-1,980	-783	188,210	637,776	128,672	4,377	231,707	26.00	14,480	6,057	-	-
Buy Backs	-100.0%	-	30,155	4,828	-	-	80,000	80,000	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SKIN Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net sales	$ 81,403	$ 86,278
Cost of sales	33,042	32,174
Gross profit	48,361	54,104
Operating expenses:
Selling and marketing	33,684	38,699
Research and development	2,807	2,336
General and administrative	28,861	30,379
Total operating expenses	65,352	71,414
Loss from operations	(16,991)	(17,310)
Interest expense	3,029	3,417
Interest income	(5,356)	(4,315)
Other income, net	(16,087)	(418)
Change in fair value of warrant liabilities	1,464	9,076
Foreign currency transaction loss (gain), net	1,297	(1,149)
Loss before provision for income taxes	(1,338)	(23,921)
Income tax benefit	(659)	(3,662)
Net loss	(679)	(20,259)
Comprehensive loss, net of tax:
Foreign currency translation adjustments	(1,047)	888
Comprehensive loss	$ (1,726)	$ (19,371)
Net loss per share
Basic (in dollars per share)	$ (0.01)	$ (0.15)
Diluted (in dollars per share)	$ (0.10)	$ (0.15)
Weighted average common shares outstanding
Basic (in shares)	123,120,426	132,420,762
Diluted (in shares)	144,477,208	132,420,762

SKIN Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash, cash equivalents, and restricted cash	$ 444,634	$ 523,025
Accounts receivable, net of allowances for estimated credit losses of $7,228 and $6,604 at March 31, 2024 and December 31, 2023, respectively	47,666	54,697
Inventories	95,721	91,321
Income tax receivable	1,204	332
Prepaid expenses and other current assets	25,599	28,877
Total current assets	614,824	698,252
Property and equipment, net	12,048	14,226
Right-of-use assets, net	16,383	12,120
Intangible assets, net	58,405	62,123
Goodwill	125,365	125,818
Deferred income tax assets, net	1,932	531
Other assets	15,784	16,043
TOTAL ASSETS	844,741	929,113
Current liabilities:
Accounts payable	37,312	44,768
Accrued payroll-related expenses	15,456	22,028
Syndeo Program reserves	8,314	21,009
Lease liabilities, current	4,648	4,598
Income tax payable	3,443	2,759
Other accrued expenses	24,395	19,846
Total current liabilities	93,568	115,008
Lease liabilities, non-current	13,688	9,319
Deferred income tax liabilities, net	1,068	702
Warrant liabilities	5,019	3,555
Convertible senior notes, net	665,486	738,372
Other long-term liabilities	2,617	2,767
Total liabilities	781,446	869,723
Commitments (Note 10)
Stockholders’ equity:
Class A Common Stock, $0.0001 par value; 320,000,000 shares authorized; 123,453,419 and 122,899,002 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	12	12
Additional paid-in capital	546,912	541,281
Accumulated other comprehensive loss	(4,083)	(3,036)
Accumulated deficit	(479,546)	(478,867)
Total stockholders’ equity	63,295	59,390
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 844,741	$ 929,113

About The Beauty Health Company

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.

CEO	Mr. Andrew Stanleick
WEBSITE	beautyhealth.com
INDUSTRY	Household Products
EMPLOYEES	1034

The Beauty Health Company Frequently Asked Questions

What is the ticker symbol for The Beauty Health Company? What does SKIN stand for in stocks?

SKIN is the stock ticker symbol of The Beauty Health Company. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of The Beauty Health Company (SKIN)?

As of Fri May 17 2024, market cap of The Beauty Health Company is 338.75 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SKIN stock?

You can check SKIN's fair value in chart for subscribers.

What is the fair value of SKIN stock?

You can check SKIN's fair value in chart for subscribers. The fair value of The Beauty Health Company is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of The Beauty Health Company is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SKIN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is The Beauty Health Company a good stock to buy?

The fair value guage provides a quick view whether SKIN is over valued or under valued. Whether The Beauty Health Company is cheap or expensive depends on the assumptions which impact The Beauty Health Company's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SKIN.

What is The Beauty Health Company's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, SKIN's PE ratio (Price to Earnings) is -4.21 and Price to Sales (PS) ratio is 0.86. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SKIN PE ratio will change depending on the future growth rate expectations of investors.